| Name | Title | Contact Details |
|---|
NextGen Pharma Technologies is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
International Oncology Network is a Frisco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovation is the leading provider of Pharmacy Intelligence™ and pharmacy automation to the retail, hospital, government, and mail order pharmacy markets. Our PharmASSIST® suite of pharmacy automation and process optimization solutions enable all types of pharmacies to increase operational efficiency, enhance patient safety, and provide a higher quality of patient care. Leveraging our unparalleled Pharmacy Intelligence, you can optimize your pharmacy fulfillment process, develop a proven ROI, and gain complete confidence in your automation decisions before investing. Innovation is a name we carry proudly. It is what we do and in many ways who we are. For three and a half decades we have been bringing new technology to industry. Our approach is simple. We start by understanding the problem and then apply all of our talent, expertise, and resources to create new and inventive ways to solve them. That is Innovation.
Metro Vein Centers is a network of trusted vein specialists and vascular surgeons, specializing in varicose veins, spider veins and other venous conditions. Book your appointment online!
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia